Cardiorespiratory fitness may be one of the most underutilized clinical tools in managing type 2 diabetes, obesity, and metabolic syndrome — conditions affecting hundreds of millions globally. A growing body of evidence suggests that how exercise is dosed and monitored matters as much as whether someone exercises at all, and that autonomic nervous system readiness may hold the key to personalizing training for higher-risk populations.
This review synthesizes evidence on how low cardiorespiratory fitness — measured via VO₂max — rivals or exceeds traditional cardiovascular risk factors like hypertension and dyslipidemia in predicting all-cause and cardiovascular mortality. Each one-MET increment in fitness was associated with meaningful reductions in mortality risk across cardiometabolic disease populations. Both aerobic and resistance exercise improved metabolic health through overlapping but distinct mechanisms: aerobic training primarily drives mitochondrial biogenesis, endothelial function, and lipoprotein remodeling, while resistance training contributes through lean mass accretion, glucose transporter upregulation, and autonomic rebalancing. High-intensity interval training demonstrated superior VO₂max gains compared to moderate-intensity continuous training, though the review flags that unmonitored high-intensity loading without recovery can impair rather than enhance adaptation. Heart rate variability-guided training — where session intensity is adjusted daily based on autonomic recovery signals — emerged as a clinically practical individualization strategy, with consumer wearables like WHOOP and Oura increasingly positioned as delivery platforms.
This review arrives at an important inflection point: wearable HRV monitoring is transitioning from athletic performance circles into clinical cardiometabolic management. The conceptual framework — treat CRF as a vital sign and titrate exercise like a drug — is not new, but the accessibility of real-time autonomic feedback tools makes implementation more feasible than in prior decades. Key limitations remain: most HRV-guided training trials are small, short-duration, and conducted in non-clinical athletic populations, leaving uncertainty about optimal protocols for individuals with significant cardiometabolic disease. Wearable device accuracy in clinical populations also requires further validation. Overall, this is a well-timed confirmatory review that strengthens the case for integrating fitness assessment and individualized training intensity into standard cardiometabolic care — an incremental but clinically meaningful contribution.
